• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

A Downward Trend of the Ratio of Influenza RNA Copy Number to Infectious Viral Titer in Hospitalized Influenza A-Infected Patients

tetano

Editor, Senior Moderator
Open Forum Infect Dis. 2015 Nov 3;2(4):ofv166. doi: 10.1093/ofid/ofv166. eCollection 2015.
[h=1]A Downward Trend of the Ratio of Influenza RNA Copy Number to Infectious Viral Titer in Hospitalized Influenza A-Infected Patients.[/h] Van Wesenbeeck L[SUP]1[/SUP], D'Haese D[SUP]1[/SUP], Tolboom J[SUP]2[/SUP], Meeuws H[SUP]1[/SUP], Dwyer DE[SUP]3[/SUP], Holmes M[SUP]4[/SUP], Ison MG[SUP]5[/SUP], Katz K[SUP]6[/SUP], McGeer A[SUP]7[/SUP], Sadoff J[SUP]2[/SUP], Weverling GJ[SUP]2[/SUP], Stuyver L[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Background.  Efficacy endpoints in influenza clinical trials may include clinical symptoms and virological measurements, although virology cannot serve as the primary endpoint. We investigated the relationship between influenza A RNA copy number and quantity of infectious viruses in hospitalized influenza patients. Methods.  One hundred fifty influenza-infected, hospitalized patients were included in this prospective cohort study spanning the 2012-2013 influenza season. Daily nasopharyngeal samples were collected during hospitalization, and influenza A RNA copy number and infectious viral titer were monitored. Results.  The decay rate for 50% tissue culture infectious dose (TCID50) was 0.51 ? 0.14 log10 TCID50/mL per day, whereas the RNA copy number decreased at a rate of 0.41 ? 0.04 log10 copies/mL per day (n = 433). The log ratio of the RNA copy number to the infectious viral titer within patient changes significantly with -0.25 ? 0.09 units per day (P = .0069). For a 12-day observation period, the decay corresponds to a decline of this ratio of 3 log influenza RNA copies. Conclusions.  Influenza RNA copy number in nasal swabs is co-linear with culture, although the rate of decay of cell culture-based viral titers was faster than that observed with molecular methods. The study documented a clear decreasing log ratio of the RNA copy number to the infectious viral titer of the patients over time.


[h=4]KEYWORDS:[/h] infectious viral titer; influenza A TCID50; influenza A viral load; influenza RNA copy number; nasopharyngeal swabs

PMID: 26677457 [PubMed]
 
Back
Top Bottom